Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers. Significant
efforts have largely defined major genetic factors driving PDAC pathogenesis and …

Organotypic models of patient-specific tumours are revolutionizing our understanding of
cancer heterogeneity and its implications for personalized medicine. These advancements …

Background Patients with borderline resectable pancreatic ductal adenocarcinoma have
relatively low resection rates and poor survival despite the use of adjuvant chemotherapy …

Despite rapid advances in modern medical technology and significant improvements in
survival rates of many cancers, pancreatic cancer is still a highly lethal gastrointestinal …

Pancreatic cancer is a devastating gastrointestinal cancer characterized by late diagnosis,
limited treatment success and dismal prognosis. Exocrine tumours account for 95% of …

Pancreatic cancer is an increasingly common cause of cancer mortality with a tight
correspondence between disease mortality and incidence. Furthermore, it is usually …

Background & Aims There were an estimated 4.8 million new cases of gastrointestinal (GI)
cancers and 3.4 million related deaths, worldwide, in 2018. GI cancers account for 26% of …

The tumor microenvironment in pancreatic ductal adenocarcinoma (PDAC) involves a
significant accumulation of fibroblasts as part of the host response to cancer. Using single …

Ras is frequently mutated in cancer, however, there is a lack of consensus in the literature
regarding the cancer mutation frequency of Ras, with quoted values varying from 10%–30 …

Cancer is one of the leading causes of death worldwide. Several treatments are available for
cancer treatment, but many treatment methods are ineffective against multidrug-resistant …